The Honest Timeline

Robert Cheng signed the consent document. Dr. Sarah Kim went back to her simulation lab. Julia Moreno went back to her office to work on hearing aid coverage. Each of them is operating on a different timeline, and the timelines do not converge. The drug Robert is testing will not benefit from the simulation infrastructure Sarah is building. The policy Julia is advancing will not affect the trial Robert enrolled in. The three preceding pieces in this series described three pipelines. This piece assembles them into the single question the reader is asking: what arrives when?

The answer requires the same temporal discipline this publication has applied from its first article. What exists now and is underused. What is genuinely two to three years away. What may arrive in five to ten years. The three timeframes do not blend into each other. They do not blur into optimism. Each carries its own honest account of what must go right for the timeline to hold.

What Exists Now and Is Underused

#

The drug pipeline described in 15.01 has already produced approved therapies. Lecanemab and donanemab are available, FDA-approved, and covered by Medicare with restrictions. They are modestly effective. They are significantly expensive. They are used by a fraction of the patients who could benefit from them. The gap between availability and use is driven by cost, by infusion burden, by ARIA risk concerns, and by a clinical community that remains divided on whether the modest functional benefit justifies the treatment’s demands.

The policy infrastructure described in 15.03 is equally available and equally underused. Medicare dental coverage does not exist, but the state pharmaceutical assistance programs, the SHIP counselors, the AAA services, and the FQHC network described in Series 14 do exist. The benefits navigation described in Series 2 can connect people to these resources today. Most people who would benefit have not been connected.

The quantum computing infrastructure described in 15.02 is the exception. It is not underused. It is not yet ready. Sarah Kim’s simulation accuracy is improving quarterly, but the drug candidates it will identify have not yet entered human trials. This pipeline is genuinely pre-clinical. It belongs in the five-to-ten-year window, not in the present.

The pattern across all three pieces is the same: what exists now is partially effective and partially deployed. The health AI from Series 1, the benefits agent from Series 2, the cognitive baseline from Series 4, the caregiver tools from Series 6, the social connection architecture from Series 7 and 8, the purpose deployment model from Series 11 and 12, the resource infrastructure from Series 14: all of these are available in forms that work. None of them waits for a trial result or a policy change. Each waits for the person who needs it to know it exists.

What to Watch Over the Next Two to Three Years

#

The developments worth following are specific and named.

Anti-tau Phase III trial results are the most important clinical development for families affected by Alzheimer’s. Robert Cheng’s trial and several others will report primary results within this window. If positive, FDA submission follows. If negative, the research direction shifts toward combination therapy and alternative mechanisms. Either outcome changes the landscape. The reader following this should watch for the primary endpoint results, not the press releases that precede them.

GLP-1 cognitive protection trial results carry a different kind of significance. If semaglutide proves effective for cognitive protection in the EVOKE trial and related studies, the implications differ from every other drug in this series. The drug is already approved, already manufactured at scale, and already prescribed to millions. The path from positive results to availability would be measured in months, not the decade that a novel biologic requires. The cost and access picture would be better, though not solved. Lisa Cheng’s question about affordability has a less painful answer if the effective drug is a repurposed one.

Multilingual AI validation for clinical applications will report results for Spanish and Mandarin within this window. The speech recognition failures that Series 13 documented are being addressed through retraining on diverse speech datasets. Whether the retrained systems reach clinical reliability for the ten most common languages among US older adults will determine whether the equity failures of Series 13 begin to close or persist.

Household robotics in the personal assistance category will reach consumers. The devices from Series 3 that retrieve dropped objects and perform simple household tasks are at commercial stage. The gap between demonstration and daily use, between the product launch and the 78-year-old who needs it working reliably in her kitchen, will become visible in this window.

BEAD broadband deployment progress is trackable by state. The timeline matters for every person described in Series 14 whose health AI requires connectivity that does not yet exist at their address. State broadband offices publish deployment schedules. The reader in a state where deployment is behind schedule has a specific advocacy target.

What Five to Ten Years May Bring

#

Each prediction in this section is grounded in current evidence and current funding trajectories. Each requires specific things to go right.

If anti-tau trials succeed: an FDA-approved anti-tau therapy. Combined with existing amyloid therapy, the combination could produce meaningfully greater functional benefit than either alone. The combination therapy model from oncology, described in 15.01, would begin its application to neurodegeneration in clinical practice. The pricing and access questions that Lisa asked would apply with the same force to the new drug.

If GLP-1 results are positive: a repurposed drug available for cognitive protection with existing manufacturing infrastructure. The metabolic-cognitive connection from Series 4 would move from research finding to clinical intervention. The population that benefits first would be the millions of people already taking GLP-1 drugs for diabetes and weight management, for whom cognitive protection would be an additional benefit of an existing prescription.

Household robotics capable of personal care assistance is advancing technically. The regulatory and liability framework for a robot that touches a person’s body is not. The technology may be ready before the legal environment permits its deployment. This gap between technical readiness and regulatory readiness is worth watching and worth advocating to close, because the population that needs the assistance cannot wait for the regulatory process to resolve itself without constituent pressure.

APOE4 gene therapy is approaching Phase II. Gene therapy for a common genetic variant is scientifically unprecedented at this scale. If it works, it addresses the genetic risk factor carried by roughly 25 percent of the population. The timeline from Phase II to availability is a decade under the most optimistic assumptions. Robert Cheng’s grandchildren are the honest audience.

Quantum-derived drug candidates entering Phase I trials: Sarah Kim’s infrastructure producing its first compounds ready for human testing. This is the longest timeline in the series. The simulation accuracy is improving. The translation from better simulation to better drug to approved treatment spans the full development cycle. The infrastructure matters. The payoff is generational.

What Requires Civic Action

#

The three preceding pieces identified five policy changes that would transform aging in America. None of them is a technology problem. Each is a political decision.

Medicare dental, vision, and hearing coverage is the most actionable. Julia Moreno named it without hesitation. The evidence base is strong. The public support is overwhelming. The opposition is industry-driven. The proposal has been introduced in every Congress for two decades. It has not passed because the people it would help have not been as loud as the people it would displace. A letter to a representative is a specific action with a specific target.

Federal paid family leave for caregivers is the structural response to the 4.5-year caregiving duration that twelve weeks of unpaid leave does not address. Nine states have programs. The federal government does not.

Broadband as healthcare infrastructure is the reclassification that would allow healthcare funding to support the connectivity that healthcare devices require. Agnes Littlefeather’s offline months are a policy classification, not a weather condition.

ADEA enforcement reform would protect the economic security that makes every other recommendation in this publication affordable. Involuntary job loss after 50 accelerates cognitive decline. Age discrimination enforcement is a health intervention.

Each of these connects directly to a person described earlier in this publication. Each is something a constituent can act on. The technology described across fifteen series works within a policy environment. The policy environment is shaped by the people who speak and the people who do not.

The Three Pipelines

#

Robert’s pipeline is the drug. The anti-tau trial he enrolled in, the GLP-1 trials running in parallel, the combination therapy concept following behind. His timeline is measured in trial results and FDA decisions. The first result arrives in one to two years. If it is positive, the drug that follows arrives in three to five. If it is negative, the next candidate enters trials and the timeline extends. Robert signed the consent document because waiting for certainty is not an option available to a 69-year-old with early Alzheimer’s.

Sarah’s pipeline is the infrastructure. The simulation platform that identifies better drug candidates faster, with fewer failures in clinical trials, producing a more efficient path from hypothesis to approved treatment. Her timeline is measured in decades. Her daughter is two. The drugs that Sarah’s infrastructure helps discover will be prescribed to people who are not yet born. She finds this sufficient.

Julia’s pipeline is the policy. The hearing aid coverage she is working on this week. The dental coverage she has been working on for fourteen years. The paid leave, the broadband, the enforcement reform. Her timeline is measured in legislative sessions and election cycles. She does not expect the full list in her career. She expects the hearing aid piece. It will not be enough. It will be something.

Three pipelines. Three timelines. None of them is fast enough for the person who needs the result today. Each of them is real, and funded, and advancing. The honest timeline does not promise that the pipelines converge in time for any specific reader. It promises that the work is happening, that the milestones are named, and that the reader who follows them will know the difference between a result and a press release.